We continue to conduct clinical studies and work with our key opinion leaders to pursue applications for which our cell-specific mechanism of action is enabling. Our application development pipeline continues to reveal additional targets that add to the utilization potential of our future growing installed base.

Specific indications have not yet been cleared by the U.S. FDA